• Kairos Pharma posted a net loss of $1.65 million for the quarter ended March 31, 2026, widening from $1.26 million a year earlier.
• Operating loss widened to $1.69 million as operating expenses climbed to $1.69 million from $1.27 million.
• Research and development spending rose to $684,000 from $493,000, while general and administrative costs increased to $1.01 million from $773,000.
• Cash and short-term investments totaled $3.68 million as of March 31, 2026; management said existing cash may not fund planned operating expenses and capital expenditure requirements for at least the next 12 months.
• Company raised $385,000 in gross proceeds from an at-the-market offering, signed a manufacturing services agreement with Patheon committing $783,000, and expanded its Lonza work scope by about $2 million for ENV105 Phase II supply preparation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022796), on May 13, 2026, and is solely responsible for the information contained therein.